CONMED Corp (CNMD) financials: revenue, earnings and cash flow
Fiscal 2016–2025 + TTM · from SEC filings · data as of November 13, 2026
Summary
CONMED’s revenue went from $764M in fiscal 2016 to $1.4B in fiscal 2025, growth of about 6.8% a year.
Net income in fiscal 2025 was $47M, a net margin of 3.4%; the best year in this period was 2024 with $132M.
Over the twelve months to September 30, 2026, revenue was $1.4B and net income $73M.
Free cash flow was $151M in fiscal 2025 and positive in 10 of the 10 years shown.
The diluted share count rose 11% over the period (dilution).
Revenue, profit and cash flow by year
Income statement
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.4B | $1.4B | $1.3B | $1.2B | $1.0B | $1.0B | $862M | $955M | $860M | $796M | $764M |
| Gross profit | $788M | $750M | $733M | $676M | $571M | $568M | $460M | $525M | $469M | $431M | $408M |
| Operating income | $136M | $103M | $200M | $121M | $70M | $110M | $46M | $79M | $71M | $47M | $38M |
| Net income | $73M | $47M | $132M | $64M | -$81M | $63M | $10M | $29M | $41M | $55M | $15M |
| EPS (diluted) | $2.41 | $1.51 | $4.25 | $2.04 | $-2.68 | $1.94 | $0.32 | $0.97 | $1.41 | $1.97 | $0.52 |
| R&D | $62M | $56M | $54M | $53M | $47M | $44M | $40M | $45M | $42M | $32M | $32M |
| Revenue growth | — | +5.2% | +5.0% | +19.1% | +3.5% | +17.2% | −9.7% | +11.1% | +7.9% | +4.3% | +6.2% |
Cash flow
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $146M | $171M | $167M | $125M | $33M | $112M | $65M | $95M | $75M | $66M | $40M |
| Capital spending | -$14M | -$20M | -$13M | -$19M | -$22M | -$15M | -$13M | -$20M | -$17M | -$13M | -$15M |
| Free cash flow | $133M | $151M | $154M | $106M | $12M | $97M | $52M | $75M | $58M | $53M | $25M |
| Dividends paid | $6M | $25M | $25M | $25M | $24M | $23M | $23M | $23M | $22M | $22M | $22M |
| Buybacks | — | — | — | — | — | — | — | — | — | — | $0 |
| Stock-based pay | $22M | $28M | $26M | $24M | $22M | $16M | $13M | $12M | $10M | $8M | $8M |
Balance sheet
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash | — | $41M | $24M | $24M | $29M | $21M | $27M | $26M | $18M | $33M | $27M |
| Debt | — | $887M | $947M | $991M | $1.1B | $705M | $776M | $793M | $457M | $486M | $498M |
| Equity | — | $1.0B | $963M | $834M | $746M | $785M | $709M | $710M | $662M | $631M | $581M |
| Total assets | — | $2.3B | $2.3B | $2.3B | $2.3B | $1.8B | $1.8B | $1.8B | $1.4B | $1.4B | $1.3B |
| Shares (diluted) | 30M | 31M | 31M | 32M | 30M | 32M | 29M | 29M | 29M | 28M | 28M |
Margins and returns
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | 57.6% | 54.6% | 56.1% | 54.3% | 54.6% | 56.2% | 53.4% | 54.9% | 54.6% | 54.1% | 53.5% |
| Operating margin | 9.9% | 7.5% | 15.3% | 9.7% | 6.7% | 10.9% | 5.3% | 8.3% | 8.3% | 5.9% | 4.9% |
| Net margin | 5.4% | 3.4% | 10.1% | 5.2% | -7.7% | 6.2% | 1.1% | 3.0% | 4.8% | 7.0% | 1.9% |
| FCF margin | 9.7% | 11.0% | 11.8% | 8.5% | 1.1% | 9.6% | 6.0% | 7.9% | 6.8% | 6.6% | 3.3% |
| ROIC | — | 3.5% | 8.5% | 5.3% | 3.0% | 6.3% | 2.5% | 4.8% | 5.1% | 3.3% | 2.6% |
| ROE | — | 4.5% | 13.8% | 7.7% | -10.8% | 8.0% | 1.3% | 4.0% | 6.2% | 8.8% | 2.5% |
Frequently asked questions
What is CONMED’s annual revenue?
$1.4B in fiscal 2025 and $1.4B over the twelve months to September 30, 2026.
How much profit does CONMED make?
Net income was $47M in fiscal 2025 (net margin 3.4%).
Is CONMED’s revenue growing?
Yes: revenue rose 5.2% in fiscal 2025 compared with the year before.
From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.